# DEXCOM INC

Summary updated: 2026-09-28T12:31:06.687392Z
Canonical: https://finbar.com/research/companies/dexcom

## Overview

Dexcom Inc. is a medical-device company that designs, develops and commercializes continuous glucose monitoring (CGM) systems for people managing diabetes and metabolic health. Its products include the Dexcom G7 CGM system and Stelo, an over-the-counter glucose biosensor designed for adults with prediabetes or Type 2 diabetes who do not use insulin. Dexcom states its mission as “Empowering People to Take Control of Health.” [1](https://app.finbar.com/go?id=P53710509)[2](https://app.finbar.com/go?id=P94647663)[3](https://investors.dexcom.com/overview/)

Founded in 1999, Dexcom operates in the United States and international markets. It reported $4.66 billion in revenue for 2025 and employed approximately 11,100 people worldwide at year-end. [3](https://investors.dexcom.com/overview/)[4](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T6400435)[6](https://app.finbar.com/go?id=P117062425)
[1](https://app.finbar.com/go?id=P53710509)[2](https://app.finbar.com/go?id=P94647663)[6](https://app.finbar.com/go?id=P117062425)[4](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T6400435)[3](https://investors.dexcom.com/overview/)

## Products & services

Dexcom’s continuous glucose monitoring (CGM) products measure glucose through wearable sensors and send readings to compatible display devices. Dexcom G7 combines its sensor and transmitter in a disposable wearable, sends readings every five minutes, and has a 30-minute warm-up and up to 10 days of wear. G7 15 Day extends wear to 15.5 days and has a 60-minute warm-up. The earlier G6 uses a separate sensor, a transmitter with a labeled three-month life, and a receiver; its sensor can be worn for up to 10 days. [7](https://app.finbar.com/go?id=P93874817)[8](https://app.finbar.com/go?id=P21901351)[9](https://app.finbar.com/go?id=P105727765)[10](https://app.finbar.com/go?id=P34630843)

Dexcom ONE and ONE+ are additional CGM offerings. ONE uses a separate sensor and transmitter and displays readings through an app or receiver; ONE+ incorporates G7’s all-in-one wearable design. Stelo is an over-the-counter glucose biosensor intended for adults with prediabetes or type 2 diabetes who do not use insulin. [11](https://app.finbar.com/go?id=P98141018)[12](https://app.finbar.com/go?id=P98882255)[13](https://app.finbar.com/go?id=P59868098)

Dexcom Clarity provides cloud-based glucose reporting and trend analysis. Share and Follow let users transmit readings and alerts to as many as ten designated people for remote monitoring. Dexcom also supports connections to compatible insulin-delivery devices, wearables and digital-health apps, and offers an API for authorized third-party uses of real-time CGM data. In 2024, disposable sensors and other products accounted for approximately 95% of revenue, versus approximately 5% from reusable hardware. [14](https://app.finbar.com/go?id=P67075618)[15](https://app.finbar.com/go?id=P5215987)[16](https://app.finbar.com/go?id=P119354538)[17](https://app.finbar.com/go?id=P86783299)[18](https://app.finbar.com/go?id=P43124271)[19](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm)
[7](https://app.finbar.com/go?id=P93874817)[8](https://app.finbar.com/go?id=P21901351)[9](https://app.finbar.com/go?id=P105727765)[10](https://app.finbar.com/go?id=P34630843)[11](https://app.finbar.com/go?id=P98141018)[12](https://app.finbar.com/go?id=P98882255)[13](https://app.finbar.com/go?id=P59868098)[14](https://app.finbar.com/go?id=P67075618)[15](https://app.finbar.com/go?id=P5215987)[16](https://app.finbar.com/go?id=P119354538)[17](https://app.finbar.com/go?id=P86783299)[18](https://app.finbar.com/go?id=P43124271)[20](https://app.finbar.com/go?id=T3685023)[19](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm)

## Geographic presence

DexCom reports revenue in two geographic categories: the United States and international markets. In 2025, U.S. revenue was $3.33 billion, or approximately 71.5% of total revenue, while international revenue was $1.33 billion, or 28.5%; it does not report revenue by individual country or international region. Its commercial activities span North America, Asia-Pacific, and Europe, the Middle East and Africa. [21](https://app.finbar.com/go?id=P33300044)[22](https://app.finbar.com/go?id=P97365170)

DexCom is headquartered in San Diego, California, where it also conducts research and development and some manufacturing. Its principal manufacturing locations are Mesa, Arizona, and Penang, Malaysia; it is also building a manufacturing facility in Athenry, Ireland. At year-end 2025, approximately 5,300 of its 11,100 employees were in the United States and 5,800 were in international locations. [23](https://app.finbar.com/go?id=P76842441)[24](https://app.finbar.com/go?id=P40140144)[25](https://app.finbar.com/go?id=P27957938)
[21](https://app.finbar.com/go?id=P33300044)[22](https://app.finbar.com/go?id=P97365170)[23](https://app.finbar.com/go?id=P76842441)[24](https://app.finbar.com/go?id=P40140144)[25](https://app.finbar.com/go?id=P27957938)

## Business segments

Dexcom reports one operating and reportable segment, managed on a global, consolidated basis. It generates revenue from disposable continuous glucose monitoring sensors and reusable hardware; Dexcom does not report separate segments or revenue shares for individual products. The single segment therefore accounts for 100% of reported revenue. [26](https://app.finbar.com/go?id=P83753986)

Dexcom also discloses revenue by geography and sales channel, but these are not separate reportable segments. In 2025, approximately 72% of revenue came from U.S. customers and 28% from international customers. Distributors accounted for approximately 85% of revenue, with direct sales accounting for the remaining 15%. [4](https://app.finbar.com/go?id=T5826161)[27](https://app.finbar.com/go?id=T3952389)
[26](https://app.finbar.com/go?id=P83753986)[4](https://app.finbar.com/go?id=T5826161)[27](https://app.finbar.com/go?id=T3952389)

## Company history

Dexcom was incorporated in 1999 and completed its initial public offering in 2005. It received FDA approval for its first continuous glucose monitoring product, the STS system, in 2006, followed by the SEVEN system in 2007 and SEVEN PLUS in 2009. [28](https://www.sec.gov/Archives/edgar/data/1093557/000104746905005246/a2152786zex-3_03.htm)[29](https://www.sec.gov/Archives/edgar/data/1093557/000104746905010113/a2155581z424b4.htm)[30](https://app.finbar.com/go?id=P193901333)

Dexcom received FDA approval for the G4 PLATINUM system in 2012. In 2015, Kevin Sayer became president and chief executive officer, succeeding Terry Gregg, and the company received FDA approval for G5 Mobile. Subsequent generations included G6, authorized in 2018, and G7, cleared in 2022 and launched in the United States in 2023. [31](https://app.finbar.com/go?id=P190282168)[32](https://investors.dexcom.com/news/news-details/2015/Kevin-Sayer-Assumes-Role-of-President-and-Chief-Executive-Officer-Terry-Gregg-Transitions-to-Role-of-Executive-Chairman/default.aspx)[33](https://investors.dexcom.com/news/news-details/2015/FDA-Approves-Dexcom-G5-Mobile-Continuous-Glucose-Monitoring-System/default.aspx)[15](https://app.finbar.com/go?id=P5215987)[34](https://app.finbar.com/go?id=P46690206)[35](https://app.finbar.com/go?id=P82115826)
[30](https://app.finbar.com/go?id=P193901333)[31](https://app.finbar.com/go?id=P190282168)[15](https://app.finbar.com/go?id=P5215987)[34](https://app.finbar.com/go?id=P46690206)[35](https://app.finbar.com/go?id=P82115826)[28](https://www.sec.gov/Archives/edgar/data/1093557/000104746905005246/a2152786zex-3_03.htm)[29](https://www.sec.gov/Archives/edgar/data/1093557/000104746905010113/a2155581z424b4.htm)[32](https://investors.dexcom.com/news/news-details/2015/Kevin-Sayer-Assumes-Role-of-President-and-Chief-Executive-Officer-Terry-Gregg-Transitions-to-Role-of-Executive-Chairman/default.aspx)[33](https://investors.dexcom.com/news/news-details/2015/FDA-Approves-Dexcom-G5-Mobile-Continuous-Glucose-Monitoring-System/default.aspx)

## Sources

1. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53710509)
2. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P94647663)
3. [investors.dexcom.com](https://investors.dexcom.com/overview/)
4. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T5826161)
5. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T6400435)
6. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P117062425)
7. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P93874817)
8. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P21901351)
9. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P105727765)
10. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P34630843)
11. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P98141018)
12. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P98882255)
13. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P59868098)
14. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P67075618)
15. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P5215987)
16. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P119354538)
17. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P86783299)
18. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P43124271)
19. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm)
20. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=T3685023)
21. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P33300044)
22. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P97365170)
23. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P76842441)
24. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P40140144)
25. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P27957938)
26. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P83753986)
27. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T3952389)
28. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1093557/000104746905005246/a2152786zex-3_03.htm)
29. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1093557/000104746905010113/a2155581z424b4.htm)
30. [DEXCOM INC — Full financial report (2010 Y)](https://app.finbar.com/go?id=P193901333)
31. [DEXCOM INC — Full financial report (2015 Y)](https://app.finbar.com/go?id=P190282168)
32. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2015/Kevin-Sayer-Assumes-Role-of-President-and-Chief-Executive-Officer-Terry-Gregg-Transitions-to-Role-of-Executive-Chairman/default.aspx)
33. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2015/FDA-Approves-Dexcom-G5-Mobile-Continuous-Glucose-Monitoring-System/default.aspx)
34. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P46690206)
35. [DEXCOM INC — Full financial report (2024 Y)](https://app.finbar.com/go?id=P82115826)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.